Valuation: Resverlogix Corp.

Market Cap 22.23M 15.95M 13.82M 13.07M 11.86M 1.53B 22.37M 156M 60.28M 776M 59.93M 58.6M 2.47B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 108M 77.51M 67.17M 63.49M 57.64M 7.44B 109M 758M 293M 3.77B 291M 285M 12.02B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 week-5.26%
Current month-5.26%
1 month-14.29%
3 months-5.26%
6 months-25.00%
Current year-10.00%
1 week 0.09
Extreme 0.09
0.1
1 month 0.09
Extreme 0.09
0.1
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap. Importance
06/07/26 Option

Chief Financial Officer

350,000 0.1018%
06/07/26 Option

Chief Financial Officer

-350,000 0.1018%
06/07/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-5.26%-5.26%+28.57% 22.26M
+0.66%+1.83%+47.32%+97.63% 69.18B
-1.19%-1.92%+34.57%+73.08% 62B
+2.22%-4.83%-15.32%+360.65% 26.19B
+0.32%+5.18%+27.38%+14.59% 25.75B
-0.89%-2.34%-3.46%-15.24% 24.29B
+2.84%+3.61%+24.60%-17.13% 19.84B
0.00%-10.41%+171.96%+298.75% 15.65B
-0.57%-1.37%-4.53%+825.13% 13.88B
-0.39%-3.41%-10.42%+452.05% 14.09B
Average +0.26%-2.37%+26.69%+211.81% 27.09B
Weighted average by Cap. +0.19%-1.18%+31.77%+158.35%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.48M -4.75M -4.49M -4.07M -526M -7.68M -53.57M -20.7M -267M -20.58M -20.12M -850M -7.77M -5.57M -4.83M -4.56M -4.14M -535M -7.81M -54.49M -21.06M -271M -20.94M -20.47M -864M
Net Debt 81.87M 58.74M 50.91M 48.12M 43.68M 5.64B 82.36M 574M 222M 2.86B 221M 216M 9.11B 85.79M 61.56M 53.35M 50.42M 45.77M 5.91B 86.3M 602M 233M 3B 231M 226M 9.55B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
16/09/26 CA$0.0900 0.00% 80,632
15/09/26 CA$0.0900 0.00% 2,600
14/09/26 CA$0.0900 0.00% 16,000
11/09/26 CA$0.0900 0.00% 75,000
10/09/26 CA$0.0900 -5.26% 42,499
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!